Ivana Samaržija1. 1. Laboratory for Epigenomics, Division of Molecular Medicine, Ruđer Bošković Institute, 10000 Zagreb, Croatia.
Abstract
While a protein primary structure is determined by genetic code, its specific functional form is mostly achieved in a dynamic interplay that includes actions of many enzymes involved in post-translational modifications. This versatile repertoire is widely used by cells to direct their response to external stimuli, regulate transcription and protein localization and to keep proteostasis. Herein, post-translational modifications with evident potency to drive prostate cancer are explored. A comprehensive list of proteome-wide and single protein post-translational modifications and their involvement in phenotypic outcomes is presented. Specifically, the data on phosphorylation, glycosylation, ubiquitination, SUMOylation, acetylation, and lipidation in prostate cancer and the enzymes involved are collected. This type of knowledge is especially valuable in cases when cancer cells do not differ in the expression or mutational status of a protein, but its differential activity is regulated on the level of post-translational modifications. Since their driving roles in prostate cancer, post-translational modifications are widely studied in attempts to advance prostate cancer treatment. Current strategies that exploit the potential of post-translational modifications in prostate cancer therapy are presented.
While a protein primary structure is determined by genetic code, its specific functional form is mostly achieved in a dynamic interplay that includes actions of many n class="Chemical">enzymes involved in post-translational modifications. This versatile repertoire is widely used by cells to direct their response to external stimuli, regulate transcription and protein localization and to keep proteostasis. Herein, post-translational modifications with evident potency to drive prostate cancerare explored. A comprehensive list of proteome-wide and single protein post-translational modifications and their involvement in phenotypic outcomes is presented. Specifically, the data on phosphorylation, glycosylation, ubiquitination, SUMOylation, acetylation, and lipidation in prostate cancer and the enzymes involved are collected. This type of knowledge is especially valuable in cases when cancer cells do not differ in the expression or mutational status of a protein, but its differential activity is regulated on the level of post-translational modifications. Since their driving roles in prostate cancer, post-translational modifications are widely studied in attempts to advance prostate cancer treatment. Current strategies that exploit the potential of post-translational modifications in prostate cancer therapy are presented.
Authors: Jung Hwa Kim; Ji Min Lee; Hye Jin Nam; Hee June Choi; Jung Woo Yang; Jason S Lee; Mi Hyang Kim; Su-Il Kim; Chin Ha Chung; Keun Il Kim; Sung Hee Baek Journal: Proc Natl Acad Sci U S A Date: 2007-12-17 Impact factor: 11.205
Authors: Michael J Gray; Jing Zhang; Lee M Ellis; Gregg L Semenza; Douglas B Evans; Stephanie S Watowich; Gary E Gallick Journal: Oncogene Date: 2005-04-28 Impact factor: 9.867
Authors: Johann S de Bono; Ugo De Giorgi; Daniel Nava Rodrigues; Christophe Massard; Sergio Bracarda; Albert Font; Jose Angel Arranz Arija; Kent C Shih; George Daniel Radavoi; Na Xu; Wai Y Chan; Han Ma; Steven Gendreau; Ruth Riisnaes; Premal H Patel; Daniel J Maslyar; Viorel Jinga Journal: Clin Cancer Res Date: 2018-07-23 Impact factor: 12.531
Authors: Hector F Valenzuela; Karen E Pace; Paula V Cabrera; Rachel White; Katja Porvari; Helena Kaija; Pirkko Vihko; Linda G Baum Journal: Cancer Res Date: 2007-07-01 Impact factor: 12.701